{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:59:44Z","timestamp":1789041584926,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Use of brentuximab vedotin (BV) and PD-1 monoclonal antibodies (mAbs) before autologous stem cell transplantation (ASCT) could impact the benefit of post-ASCT BV maintenance in relapsed\/refractory (R\/R) classic Hodgkin lymphoma (cHL). We identified 1091 patients with R\/R cHL who underwent ASCT between 2010-2022. In total, 244 (22%) received a PD-1 mAb and 443 (41%) received BV before ASCT, while 305 (28%) received BV maintenance. We performed 1:1 propensity score matching to assess the efficacy of BV maintenance in different patient subgroups. Among 608 matched patients, the 3-year progression-free survival (PFS) and overall survival were 73% (95% confidence interval [CI], 70-78) and 95% (95%CI, 93-97), respectively. BV maintenance was associated with improved PFS for patients with no exposure to novel agents, especially those with 2+ modified AETHERA risk factors (0-1 factors: hazard ratio (HR), 0.51; 95%CI, 0.24-1.09; P =.083; 2+ factors: HR, 0.40; 95%CI, 0.25-0.65; P&amp;lt; .001). In contrast, BV maintenance was not associated with a significant PFS benefit for any patient subgroup who received novel agents before ASCT (BV-treated, 0-1: HR, 1.43; 95%CI, 0.53-3.81; P =.48; 2+: HR, 0.79; 95%CI, 0.34-1.82; P =.58; PD-1-treated, 0-1 [P&amp;gt;.99], 2+: HR, 0.25; 95%CI, 0.03-2.14; P =.21). In particular, we observed excellent outcomes for patients undergoing ASCT in a complete response after one line of PD-1-based salvage treatment with no significant benefit for BV maintenance observed (2-year PFS 100% vs 95%; P&amp;gt;.99). The benefit of BV maintenance appears to be attenuated for patients receiving novel agents with salvage therapy. Omission of BV maintenance should be considered for patients anticipated to have excellent outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018683","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:53:54Z","timestamp":1774644834000},"page":"3833-3844","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-6998","authenticated-orcid":false,"given":"Ayo S.","family":"Falade","sequence":"first","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2625","authenticated-orcid":false,"given":"Sanjal H.","family":"Desai","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"},{"name":"3Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"4Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[{"name":"4Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7751-8429","authenticated-orcid":false,"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[{"name":"4Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-4495","authenticated-orcid":false,"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"4Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Nedved","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay She","family":"Ng","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7322","authenticated-orcid":false,"given":"Kelsey","family":"Baron","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-6975","authenticated-orcid":false,"given":"Shin Yeu","family":"Ong","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yoon","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, UCLA Medical Center Olive View, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Iyengar","sequence":"additional","affiliation":[{"name":"9Division of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Micallef","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert","family":"Stuver","sequence":"additional","affiliation":[{"name":"4Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"10Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[{"name":"10Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"9980","key":"2026060911322058200_bib1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"The Lancet"},{"issue":"25","key":"2026060911322058200_bib2","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"2026060911322058200_bib3","unstructured":"Seattle Genetics Announces FDA Regular Approval of ADCETRIS\u00ae (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation. 17 August 2015. Accessed 9 January 2024. https:\/\/www.fiercepharma.com\/pharma\/seattle-genetics-announces-fda-regular-approval-of-adcetris\u00ae-brentuximab-vedotin-for."},{"issue":"4","key":"2026060911322058200_bib4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"2026060911322058200_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026060911322058200_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2026060911322058200_bib7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2022-167626","article-title":"Nivolumab plus ICE as first salvage therapy in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"140","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026060911322058200_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/OP.20.01020","article-title":"PD-1 blockade in classic Hodgkin lymphoma","volume":"17","author":"Ansell","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"2026060911322058200_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/OP.20.00771","article-title":"Checkpoint inhibition therapy in transplant-ineligible relapsed or refractory classic Hodgkin lymphoma","volume":"17","author":"Al-Hadidi","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"suppl 1","key":"2026060911322058200_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2021-145111","article-title":"Pembrolizumab (PEM) added to ICE chemotherapy results in high complete metabolic response rates in relapsed\/refractory classic Hodgkin lymphoma (cHL): a multi-institutional phase II trial","volume":"138","author":"Bryan","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026060911322058200_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"28","key":"2026060911322058200_bib12","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026060911322058200_bib13","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide (DD-BV-ICE) for second line treatment of relapsed\/refractory classical Hodgkin lymphoma: a single center phase I\/II study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026060911322058200_bib14","unstructured":"Desai\n              S\n            , ReidM, HarshS, . PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort. Paper presented at: ASH Annual Meeting; 9 December 2023. San Diego. Accessed 27 January 2025. https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper179573.html."},{"issue":"4","key":"2026060911322058200_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026060911322058200_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"10450","key":"2026060911322058200_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"The Lancet"},{"issue":"15","key":"2026060911322058200_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2026060911322058200_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2026060911322058200_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.2939","article-title":"Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience","volume":"40","author":"Massaro","year":"2022","journal-title":"Hematol Oncol"},{"issue":"4","key":"2026060911322058200_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/hon.2897","article-title":"Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: multicenter retrospective study","volume":"39","author":"Akay","year":"2021","journal-title":"Hematol Oncol"},{"issue":"10","key":"2026060911322058200_bib22","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41409-023-02036-x","article-title":"Contemporary outcomes of high risk relapsed refractory classical Hodgkin lymphoma patients\u2014role of maintenance therapy in the real world","volume":"58","author":"Damlaj","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"suppl 1","key":"2026060911322058200_bib23","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1182\/blood-2022-167644","article-title":"Real life analysis of brentuximab vedotin (BV) use as consolidation therapy in patients with Hodgkin\u2019s lymphoma (HL) with high risk of relapse after autologous stem cell transplantation (ASCT). A retrospective analysis of the EBMT Lymphoma Working Party","volume":"140","author":"Martinez Munoz","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026060911322058200_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-022-05011-6","article-title":"Impact of pre- and\/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma","volume":"102","author":"Mart\u00ednez","year":"2023","journal-title":"Ann Hematol"},{"key":"2026060911322058200_bib25","unstructured":"Munoz\n              M\n            , KhvedelidzeI, FekomM, . Outcomes of patients with Hodgkin lymphoma receiving brentuximab vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group. Paper presented at: ASH Annual Meeting; 7 December 2024. San Diego. Accessed 27 January 2025. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper205007.html."},{"issue":"7","key":"2026060911322058200_bib26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3324\/haematol.2021.279564","article-title":"Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study","volume":"107","author":"Marouf","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026060911322058200_bib27","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1182\/blood-2019-129295","article-title":"Brentuximab vedotin as consolidation therapy post hematopoietic stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a real world analysis of the Colombian Experience","volume":"134","author":"Pati\u00f1o","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2026060911322058200_bib28","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00277-023-05354-8","article-title":"Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era \u2014 real-world data from Hungary","volume":"102","author":"Husi","year":"2023","journal-title":"Ann Hematol"},{"key":"2026060911322058200_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.HS9.0000890984.54786.aa","article-title":"P104: consolidation therapy with brentuximab vedotin after autologous stem cell transplantation for relapsed\/refractory Hodgkin lymphoma in the Czech Republic","volume":"6","author":"Michalka","year":"2022","journal-title":"HemaSphere"},{"issue":"6","key":"2026060911322058200_bib30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41409-025-02557-7","article-title":"Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"60","author":"Sureda","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026060911322058200_bib31","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","article-title":"Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes","volume":"108","author":"Wagner","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2026060911322058200_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41409-025-02568-4","article-title":"Outcomes of patients with Hodgkin lymphoma receiving brentuximab vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group","volume":"60","author":"Mart\u00ednez","year":"2025","journal-title":"Bone Marrow Transpl"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3833\/2523409\/blooda_adv-2025-018683-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3833\/2523409\/blooda_adv-2025-018683-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:32Z","timestamp":1781019152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3833\/567463\/Impact-of-novel-therapies-on-the-efficacy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018683","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,27]]}}}